

Hector Chinoy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/713848/publications.pdf>

Version: 2024-02-01

199
papers

7,017
citations

81889

39
h-index

69246

77
g-index

204
all docs

204
docs citations

204
times ranked

6323
citing authors

#	ARTICLE	IF	CITATIONS
1	Limb girdle muscular dystrophy R12 (LGMD 2L, anoctaminopathy) mimicking idiopathic inflammatory myopathy: key points to prevent misdiagnosis. <i>Rheumatology</i> , 2022, 61, 1645-1650.	1.9	10
2	Contribution of Rare Genetic Variation to Disease Susceptibility in a Large Scandinavian Myositis Cohort. <i>Arthritis and Rheumatology</i> , 2022, 74, 342-352.	5.6	7
3	Adult idiopathic inflammatory myopathies. <i>Medicine</i> , 2022, 50, 70-75.	0.4	4
4	COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. <i>Rheumatology International</i> , 2022, 42, 23-29.	3.0	37
5	A systematic review and meta-analysis of mycobacterial infections in patients with idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2022, 61, 3521-3533.	1.9	5
6	Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study. <i>Indian Journal of Rheumatology</i> , 2022, 17, 188.	0.4	14
7	The role of protein aggregation in the pathogenesis of inclusion body myositis.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 414-424.	0.8	5
8	The perils of myositis mimickers with illustrative case reports. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 366-372.	0.8	1
9	Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app. <i>Rheumatology</i> , 2022, 61, 4845-4854.	1.9	4
10	British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2022, 61, 1760-1768.	1.9	37
11	The perils of myositis mimickers with illustrative case reports.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 366-372.	0.8	0
12	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS).. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 214-218.	0.8	0
13	The role of protein aggregation in the pathogenesis of inclusion body myositis.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 414-424.	0.8	0
14	P222&fClinical features of extra-muscular disease in dermatomyositis and anti-synthetase syndrome patients with skin involvement classified by presence of disease-specific autoantibodies: results from the EuroMyositis registry. <i>Rheumatology</i> , 2022, 61, .	1.9	0
15	COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. <i>Rheumatology</i> , 2022, 62, 65-76.	1.9	19
16	Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5&Yyears after diagnosis. <i>Clinical Rheumatology</i> , 2021, 40, 231-238.	2.2	11
17	Focal hamstring muscle oedema and atrophy post-anterior cruciate ligament reconstruction mimicking focal myositis. <i>Rheumatology</i> , 2021, 60, 984-985.	1.9	0
18	COVID-19 and myositis " unique challenges for patients. <i>Rheumatology</i> , 2021, 60, 907-910.	1.9	39

#	ARTICLE	IF	CITATIONS
19	Relapsing polychondritis of the nose and lower respiratory tract. <i>Rheumatology</i> , 2021, 60, e41-e43.	1.9	1
20	In Pursuit of an Effective Treatment: the Past, Present and Future of Clinical Trials in Inclusion Body Myositis. <i>Current Treatment Options in Rheumatology</i> , 2021, 7, 63-81.	1.4	3
21	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021, 60, 2615-2628.	1.9	69
22	Efficacy and Safety of Bimagrumb in Sporadic Inclusion Body Myositis. <i>Neurology</i> , 2021, 96, e1595-e1607.	1.1	25
23	Analysis of human total antibody repertoires in TIF1 β autoantibody positive dermatomyositis. <i>Communications Biology</i> , 2021, 4, 419.	4.4	9
24	P150 β Hand-held dynamometry may provide a valid and objective method of muscle strength quantification in adult inflammatory myopathy: results from clinical practice in a tertiary centre. <i>Rheumatology</i> , 2021, 60, .	1.9	1
25	The avalanche of antirheumatic therapy and COVID-19 vaccinations. <i>Rheumatology</i> , 2021, 60, 3490-3491.	1.9	2
26	P156 β Myositis flares are associated with reduced work productivity and fewer hours worked: illustration of the future potential of digital healthcare solutions in rheumatic diseases. <i>Rheumatology</i> , 2021, 60, .	1.9	0
27	P192 β Secukinumab provides rapid and sustained improvements in subgroup analyses of joint tenderness and swelling in patients with psoriatic arthritis: 2-year results from the Phase 3 FUTURE 5 study. <i>Rheumatology</i> , 2021, 60, .	1.9	0
28	POS0288 β ...A KEY TIF1 β EPI TOPE MAY FACILITATE THE IDENTIFICATION OF PATIENTS AT HIGHEST RISK OF CANCER ASSOCIATED MYOSITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 369.2-370.	0.9	0
29	Perspectives on glucocorticoid usage in patients with adult inflammatory myopathy. <i>Clinical Rheumatology</i> , 2021, 40, 4977-4982.	2.2	1
30	The relationship between rheumatoid arthritis and diabetes mellitus: a systematic review and meta-analysis. <i>Cardiovascular Endocrinology and Metabolism</i> , 2021, 10, 125-131.	1.1	25
31	Antibody responses to single β dose SARS β CoV β 2 vaccination in patients receiving immunomodulators for immune β mediated inflammatory disease. <i>British Journal of Dermatology</i> , 2021, 185, 646-648.	1.5	30
32	Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle. <i>Frontiers in Genetics</i> , 2021, 12, 702547.	2.3	18
33	The challenges of antirheumatic therapy and travel-associated infections. <i>Rheumatology</i> , 2021, , .	1.9	0
34	Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. <i>Rheumatology</i> , 2021, 60, 3398-3403.	1.9	27
35	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1275-1287.	10.7	394
36	Inflammatory Arthropathy in the Elite Sports Athlete. <i>Current Sports Medicine Reports</i> , 2021, 20, 577-583.	1.2	2

#	ARTICLE	IF	CITATIONS
37	Diagnosis of spinal tuberculosis in an Asian patient with unexplained chronic back pain. Rheumatology, 2021, , .	1.9	2
38	The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients. Rheumatology, 2020, 59, 1626-1631.	1.9	10
39	O33â€fEarlier cancer diagnosis after myositis onset is associated with improved long term survival: results from UK, French and Czech cohorts. Rheumatology, 2020, 59, .	1.9	0
40	P72â€fMuscle weakness affects function differently in males and females in inclusion body myositis: providing results for focused clinical care and clinical trial design. Rheumatology, 2020, 59, .	1.9	0
41	P253â€fSecukinumab provides sustained improvements in tender and swollen joint counts: 5year results from the Phase 3 FUTURE 2 study. Rheumatology, 2020, 59, .	1.9	0
42	P254â€fSecukinumab provides rapid and sustained improvement in joint tenderness and swelling in patients with PsA: 2-year results from the Phase 3 FUTURE 5 study. Rheumatology, 2020, 59, .	1.9	0
43	Monitoring disease activity and damage in adult and juvenile idiopathic inflammatory myopathy. Current Opinion in Rheumatology, 2020, 32, 553-561.	4.3	11
44	Patient insights on living with idiopathic inflammatory myopathy and the limitations of disease activity measurement methods â€“ a qualitative study. BMC Rheumatology, 2020, 4, 47.	1.6	9
45	Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results. BMC Rheumatology, 2020, 4, 28.	1.6	16
46	Response to: â€Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the futureâ€™ by Wang et al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-218712.	0.9	4
47	Insights into the knowledge, attitude and practices for the treatment of idiopathic inflammatory myopathy from a cross-sectional cohort survey of physicians. Rheumatology International, 2020, 40, 2047-2055.	3.0	7
48	MicroRNA and mRNA profiling in the idiopathic inflammatory myopathies. BMC Rheumatology, 2020, 4, 25.	1.6	12
49	Can machine learning unravel the complex IIM spectrum?. Nature Reviews Rheumatology, 2020, 16, 299-300.	8.0	4
50	Longâ€term strength and functional status in inclusion body myositis and identification of trajectory subgroups. Muscle and Nerve, 2020, 62, 76-82.	2.2	21
51	Pitfalls in the diagnosis of myositis. Best Practice and Research in Clinical Rheumatology, 2020, 34, 101486.	3.3	17
52	Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS. Journal of Rheumatology, 2020, 47, 1204-1208.	2.0	10
53	Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. Rheumatology, 2020, 59, 1026-1030.	1.9	16
54	Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis. Annals of the Rheumatic Diseases, 2020, 79, 1383-1386.	0.9	59

#	ARTICLE	IF	CITATIONS
55	Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Myopathy. Journal of Clinical Rheumatology, 2020, 26, e230-e231.	0.9	0
56	Myositis Basics/Who Gets Myositis. , 2020, , 7-15.		0
57	SAT0631-HPR...WHEN CAN I STOP MY STEROIDS? THE PATIENT PERSPECTIVE ON GLUCOCORTICOID USAGE IN ADULT INFLAMMATORY MYOPATHY. Annals of the Rheumatic Diseases, 2020, 79, 1275.1-1276.	0.9	0
58	OP0094...EULAR-ACR 2019 CLASSIFICATION CRITERIA FOR SLE: CAN WE CLASSIFY USING LABORATORY TESTS ALONE?. Annals of the Rheumatic Diseases, 2020, 79, 62.2-62.	0.9	0
59	SAT0331...CHIPPING AWAY AT POLYMYOSITIS: A RETROSPECTIVE REVIEW AT A TERTIARY MYOSITIS CENTRE. Annals of the Rheumatic Diseases, 2020, 79, 1111-1112.	0.9	1
60	Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria. Rheumatology, 2019, 58, 2331-2333.	1.9	4
61	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurology, The, 2019, 18, 834-844.	10.2	91
62	Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis: Reply. Rheumatology, 2019, 58, 2073-2074.	1.9	3
63	Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. PLoS ONE, 2019, 14, e0218115.	2.5	18
64	A review of accelerometer-derived physical activity in the idiopathic inflammatory myopathies. BMC Rheumatology, 2019, 3, 41.	1.6	18
65	211...Is HLA-B27 a predictor of treatment response to biologics in psoriatic arthritis?. Rheumatology, 2019, 58, .	1.9	2
66	219...Converting patients with chronic myositis from maintenance intravenous immunoglobulin therapy to rituximab in England: a potential saving of £1.7 million per year. Rheumatology, 2019, 58, .	1.9	0
67	221...Quantitative strength profiling in inclusion body Myositis: faster deterioration in males and positive associations with functional assessment tools. Rheumatology, 2019, 58, .	1.9	0
68	222...Investigating the sensitivity and specificity of the myositis profile-4 EUROLINE assay. Rheumatology, 2019, 58, .	1.9	0
69	E086...Clinical and serological features of increased interferon-alpha activity in an unselected connective tissue disease cohort. Rheumatology, 2019, 58, .	1.9	0
70	Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles. Arthritis Research and Therapy, 2019, 21, 147.	3.5	20
71	Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the <sc>UK</sc> Clinical Practice Research Datalink. Clinical Pharmacology and Therapeutics, 2019, 106, 1353-1361.	4.7	44
72	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Annals of the Rheumatic Diseases, 2019, 78, 996-1002.	0.9	81

#	ARTICLE	IF	CITATIONS
73	Discrepancy between solid-phase immunoassays and immunoprecipitation in detecting anti-TIF1 gamma in patients with myositis. <i>Rheumatology</i> , 2019, 58, .	1.9	0
74	Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies. <i>Frontiers in Immunology</i> , 2019, 10, 848.	4.8	54
75	Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. <i>Journal of Autoimmunity</i> , 2019, 101, 48-55.	6.5	184
76	The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature. <i>Dermatology and Therapy</i> , 2019, 9, 373-381.	3.0	2
77	Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review. <i>Autoimmunity Reviews</i> , 2019, 18, 535-541.	5.8	26
78	[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 657-662.	0.9	24
79	Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis. <i>Current Opinion in Rheumatology</i> , 2019, 31, 611-616.	4.3	18
80	Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. <i>Rheumatology</i> , 2019, 58, 889-896.	1.9	35
81	The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-“positive dermatomyositis. <i>Rheumatology</i> , 2019, 58, 650-655.	1.9	66
82	The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort. <i>Rheumatology</i> , 2019, 58, 468-475.	1.9	22
83	Rapamycin for inclusion body myositis: targeting non-inflammatory mechanisms. <i>Rheumatology</i> , 2019, 58, 375-376.	1.9	10
84	Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1530-1534.	2.4	11
85	Idiopathic inflammatory myopathies. <i>Medicine</i> , 2018, 46, 140-145.	0.4	3
86	Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 602-611.	0.9	51
87	Using serum troponins to screen for cardiac involvement and assess disease activity in the idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2018, 57, 1041-1046.	1.9	32
88	Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. <i>Rheumatology</i> , 2018, 57, 1896-1907.	1.9	43
89	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 30-39.	0.9	183
90	Impact of Disease Severity, Illness Beliefs, and Coping Strategies on Outcomes in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 295-302.	3.4	22

#	ARTICLE	IF	CITATIONS
91	i169â€fResearch update. Rheumatology, 2018, 57, .	1.9	0
92	O23â€fThe incidence of adult idiopathic inflammatory myopathies at a UK specialist neuromuscular centre: a ten-year epidemiology study. Rheumatology, 2018, 57, .	1.9	0
93	THU0013â€f...Downregulation of microrna may contribute to activation of the interferon signalling pathway in the idiopathic inflammatory myopathies. , 2018, , .		0
94	Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab. BMJ Case Reports, 2018, 2018, bcr-2017-223249.	0.5	11
95	i117â€fMICHAEL MASON WINNER 2018. Rheumatology, 2018, 57, .	1.9	0
96	122â€fHigh burden of immunosuppressant use in undifferentiated connective tissue disease: results from the Lupus Extended Autoimmune Phenotype Study (LEAP) cohort. Rheumatology, 2018, 57, .	1.9	0
97	Increasing incidence of adult idiopathic inflammatory myopathies in the City of Salford, UK: a 10-year epidemiological study. Rheumatology Advances in Practice, 2018, 2, rky035.	0.7	15
98	169â€fSecukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies. Rheumatology, 2018, 57, .	1.9	0
99	O67â€fA regional survey and audit of service provision for giant cell arteritis. Rheumatology, 2018, 57, .	1.9	0
100	Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2018, 30, 606-613.	4.3	17
101	253â€fSignatures of microbial and autoantibody epitopes in idiopathic inflammatory myopathies. Rheumatology, 2018, 57, .	1.9	0
102	Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-Î³ autoantibodies in adult patients with myositis. Arthritis Research and Therapy, 2018, 20, 117.	3.5	16
103	127â€fQuality of life in patients with connective tissue diseases: results from the Lupus Extended Autoimmune Phenotype (LEAP) study. Rheumatology, 2018, 57, .	1.9	1
104	117â€fAnti-TIF-1 antibody positivity is associated with a five-fold increase in cancer risk in the idiopathic inflammatory myopathies. Rheumatology, 2018, 57, .	1.9	0
105	OP0148â€f...A validation of the 2017 eular/acr idiopathic inflammatory myopathies classification criteria in an expert-defined single-centre ten year incident cohort. , 2018, , .		0
106	SP0041â€f...Win session: what is new in the treatment of myositis?. , 2018, , .		0
107	FRI0455â€f...Increasing incidence of adult idiopathic inflammatory myopathies: a ten-year uk epidemiological study. , 2018, , .		0
108	Immuneâ€fArray Analysis in Sporadic Inclusion Body Myositis Reveals HLAâ€f“DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. Arthritis and Rheumatology, 2017, 69, 1090-1099.	5.6	41

#	ARTICLE	IF	CITATIONS
109	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 208-213.	0.9	49
110	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. <i>RMD Open</i> , 2017, 3, e000314.	3.8	29
111	Cytosolic 5â€²-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 862-868.	0.9	71
112	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017, 69, 898-910.	5.6	52
113	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1955-1964.	0.9	754
114	Serum muscle damage markers in the idiopathic inflammatory myopathies: quantifying disease activity and identifying cardiac involvement. <i>Neuromuscular Disorders</i> , 2017, 27, S39-S40.	0.6	1
115	Idiopathic inflammatory myopathies â€” a guide to subtypes, diagnostic approach and treatment. <i>Clinical Medicine</i> , 2017, 17, 322-328.	1.9	39
116	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. <i>RMD Open</i> , 2017, 3, e000507.	3.8	115
117	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. <i>Arthritis and Rheumatology</i> , 2017, 69, 2271-2282.	5.6	391
118	11.â€¦A comparative study of the clinical features of dermatomyositis in child and in adult patients where the Anti-Mi-2 antibody is present. <i>Rheumatology</i> , 2017, 56, .	1.9	0
119	Response to: â€”Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteriaâ€” by Cavagna et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 77, annrheumdis-2017-212382.	0.9	2
120	PO203â€¦Assessing disease activity and cardiac involvement in myositis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A65.2-A65.	1.9	0
121	Rheumatology training in Poland vs. United Kingdom. <i>Reumatologia</i> , 2017, 3, 120-124.	1.1	1
122	A Literature Review of Eosinophilic Fasciitis with an Illustrative Case. <i>Current Rheumatology Reviews</i> , 2017, 13, 113-120.	0.8	4
123	Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease. <i>Reumatologia</i> , 2016, 1, 35-37.	1.1	5
124	Distress, misperceptions, poor coping and suicidal ideation in psoriatic arthritis: a qualitative study. <i>Rheumatology</i> , 2016, 55, 1047-1052.	1.9	13
125	Drug-specific risk, and associated factors, of vasculitis-like events in patients exposed to tumour necrosis factor alpha inhibitor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). <i>Lancet, The</i> , 2016, 387, S55.	13.7	1
126	Simple tool in a complex case: use of the nailfold capillaroscopy. <i>Kidney International</i> , 2016, 89, 1168.	5.2	1

#	ARTICLE	IF	CITATIONS
127	A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. <i>Rheumatology</i> , 2016, 55, 2131-2137.	1.9	14
128	Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. <i>Neurobiology of Aging</i> , 2016, 47, 218.e1-218.e9.	3.1	40
129	The risk of postoperative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 86-91.	2.4	24
130	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. <i>Rheumatology</i> , 2016, 55, 2050-2055.	1.9	14
131	The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome. <i>Rheumatology</i> , 2016, 55, 2277-2278.	1.9	16
132	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , 2016, 18, 156.	3.5	4
133	New developments in genetics of myositis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 651-656.	4.3	21
134	Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. <i>Journal of Rheumatology</i> , 2016, 43, 1713-1717.	2.0	77
135	Disease specificity of autoantibodies to cytosolic 5â€²-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 696-701.	0.9	116
136	Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies. <i>Journal of Rheumatology</i> , 2016, 43, 169-176.	2.0	14
137	Scalp Necrosis Associated with Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2016, 374, e6.	27.0	5
138	Pheochromocytoma in association with focal dermatomyositis. <i>Rheumatology</i> , 2016, 55, 953-954.	1.9	1
139	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1558-1566.	0.9	127
140	Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 880-884.	0.8	7
141	Exploring new mechanisms of weakness-induction, further dissection of clinical phenotypes and identification of new biomarkers in the idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2015, 27, 577-579.	4.3	0
142	The role of microRNAs in the idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2015, 27, 608-615.	4.3	31
143	O10.â€fRisk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2015, , .	1.9	0
144	Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 795-798.	0.9	74

#	ARTICLE	IF	CITATIONS
145	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015, 385, S48.	13.7	18
146	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	5.6	90
147	Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. <i>Genes and Immunity</i> , 2015, 16, 470-480.	4.1	103
148	Gene-Gene and Gene-Environment Interactions in Defining Risk and Spectrum of Phenotypes in Idiopathic Inflammatory Myopathies. , 2014, , 115-132.		0
149	Phenotype Standardization for Statin-Induced Myotoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 470-476.	4.7	166
150	GATM gene variants and statin myopathy risk. <i>Nature</i> , 2014, 513, E1-E1.	27.8	30
151	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. <i>Arthritis Care and Research</i> , 2014, 66, 1410-1416.	3.4	21
152	Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors. <i>British Journal of Dermatology</i> , 2014, 170, 995-996.	1.5	0
153	Genotyping of immune-related genetic variants identifies <i>TYK2</i> as a novel associated locus for idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1750-1752.	0.9	25
154	The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. <i>Rheumatology</i> , 2014, 53, 213-222.	1.9	177
155	Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2014, 25, 61-62.	2.2	1
156	Strategies for Evaluating Idiopathic Inflammatory Myopathy Disease Susceptibility Genes. <i>Current Rheumatology Reports</i> , 2014, 16, 446.	4.7	5
157	Testing the role of vitamin D in response to antitumour necrosis factor \pm therapy in a UK cohort: a Mendelian randomisation approach. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 938-940.	0.9	6
158	Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey. <i>Clinical Medicine</i> , 2014, 14, 95-96.	1.9	10
159	Effect of immunogenicity on efficacy of long-term treatment of rheumatoid arthritis with adalimumab. <i>Lancet, The</i> , 2014, 383, S60.	13.7	1
160	OP0235...Genetic Risk Factors in Idiopathic Inflammatory Myopathies Are Shared with Other Autoimmune Disorders in European Populations. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 151.1-151.	0.9	0
161	SAT0052...Influence of Immunogenicity and Drug Levels on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab and Etanercept: A Uk-Based Prospective Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 608.1-608.	0.9	7
162	Rituximab-associated Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, E41-E43.	1.9	28

#	ARTICLE	IF	CITATIONS
163	Statin-induced necrotizing myositis – A discrete autoimmune entity within the –statin-induced myopathy spectrum–. Autoimmunity Reviews, 2013, 12, 1177-1181.	5.8	74
164	Ustekinumab for psoriatic arthritis: close to the PSUMMIT?. Lancet, The, 2013, 382, 748-749.	13.7	2
165	Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST) Tj ETQq1 1 0.784314 rgBT /Ove	1.5	130
166	Genome–Wide Association Study of Dermatomyositis Reveals Genetic Overlap With Other Autoimmune Disorders. Arthritis and Rheumatism, 2013, 65, 3239-3247.	6.7	113
167	Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology, 2013, 52, 1728-1729.	1.9	33
168	Entering a new phase of immunogenetics in the idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2013, 25, 735-741.	4.3	19
169	Editorial. Current Opinion in Rheumatology, 2013, 25, 726-728.	4.3	2
170	Time for a –joint–™ approach?. British Journal of Dermatology, 2013, 168, 683-684.	1.5	7
171	SAT0189–Use of Anti-200/100 Antibody in the Evaluation of Statin Induced Myositis: Experience of a UK Based Tertiary Myositis-Referral Centre. Annals of the Rheumatic Diseases, 2013, 72, A645.1-A645.	0.9	0
172	Polymyositis and dermatomyositis. , 2013, , 1009-1020.		4
173	Polymyositis and dermatomyositis. , 2013, , 1009-1020.		2
174	Association of an MHC Class II Haplotype with Increased Risk of Polymyositis in Hungarian Vizsla Dogs. PLoS ONE, 2013, 8, e56490.	2.5	16
175	Genetic association study of NF-ÎB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy. Rheumatology, 2012, 51, 794-799.	1.9	30
176	Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Annals of the Rheumatic Diseases, 2012, 71, 961-965.	0.9	100
177	Recent advances in the immunogenetics of idiopathic inflammatory myopathy. Arthritis Research and Therapy, 2011, 13, 216.	3.5	38
178	Academic training in rheumatology in 2009: a UK trainee survey. Clinical Medicine, 2011, 11, 434-437.	1.9	4
179	Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy. Rheumatology, 2010, 49, 1699-1705.	1.9	37
180	Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Annals of the Rheumatic Diseases, 2009, 68, 1621-1625.	0.9	161

#	ARTICLE	IF	CITATIONS
181	HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2009, 48, 1213-1217.	1.9	41
182	Autoantibodies to a 140 kDa protein in juvenile dermatomyositis are associated with calcinosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1807-1814.	6.7	206
183	Defining cancer risk in dermatomyositis. Part I. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 451-455.	1.3	54
184	Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 561-565.	1.3	38
185	An update on the immunogenetics of idiopathic inflammatory myopathies: major histocompatibility complex and beyond. <i>Current Opinion in Rheumatology</i> , 2009, 21, 588-593.	4.3	20
186	The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 3247-3254.	6.7	56
187	Clinical, serological and HLA profiles in non-Caucasian UK idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2008, 48, 591-592.	1.9	11
188	The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1345-1349.	0.9	291
189	HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. <i>Rheumatology</i> , 2007, 46, 1786-1791.	1.9	102
190	Tumour necrosis factor- α single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2007, 46, 1411-1416.	1.9	44
191	Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. <i>Rheumatology</i> , 2007, 47, 324-328.	1.9	186
192	Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 970-973.	0.9	32
193	In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. <i>Arthritis Research and Therapy</i> , 2006, 8, R13.	3.5	110
194	Serum alanine aminotransferase elevations correlate with serum creatine phosphokinase levels in myositis. <i>Rheumatology</i> , 2006, 45, 487-488.	1.9	19
195	Monocyte chemotactic protein-1 single nucleotide polymorphisms do not confer susceptibility for the development of adult onset polymyositis/dermatomyositis in UK Caucasians. <i>Rheumatology</i> , 2006, 46, 604-607.	1.9	15
196	Have recent immunogenetic investigations increased our understanding of disease mechanisms in the idiopathic inflammatory myopathies?. <i>Current Opinion in Rheumatology</i> , 2004, 16, 707-713.	4.3	24
197	Wegener's granulomatosis and rheumatoid arthritis overlap. <i>British Journal of Rheumatology</i> , 2002, 41, 588-589.	2.3	21
198	The effect of the Covid-19 pandemic on illness perceptions of psoriasis and the role of depression: Findings from a cross-sectional study. <i>Skin Health and Disease</i> , 0, , .	1.5	1

#	ARTICLE	IF	CITATIONS
199	Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Skin Health and Disease, 0, , .	1.5	2